학술논문
FUNDAMENTAL AND CLINICAL STUDIES ON INTRAVENOUS DRIP INFUSION OF DIBEKACIN IN THE PEDIATRIC FIELD / 小児科領域におけるDibekacin点滴静注の基礎的・臨床的検討
Document Type
Journal Article
Author
AKIHIKO KIMURA; AKIRA KAWAKAMI; CHIHEI TANAKA; DAISAKU URABE; EIICHIRO ONO; EIICHIRO TANAKA; EIJI KATO; ETSUO OHTAKI; FUJIKO HIROSE; FUMIO YAMASHITA; HARUHIKO EGUCHI; HIROFUMI SAKAMOTO; HIROSHI ANDO; HIROSHI MATSUO; HIROYUKI CHO; HISAAKI ARAKI; JUN MORITA; JUNKO KAJIYAMA; KAORU KUBOTA; KAORU TOMINAGA; KATSUHIKO HIRATA; KEIKO ODA; KEIZO OHBU; KEN KIMURA; KEN YUGE; KIMIKO HARA; KIYOTAKA NAGAYAMA; KOICHI TANAKA; KOJI ISHIMOTO; KOTARO ICHIKAWA; MASAHIKO FUJIMATSU; MASANAGA YOSHIMOTO; MASANORI OHTA; MASASHI YAMAMOTO; MIZUHO HORIKAWA; MOTOHIKO HARADA; NAOFUMI TOMITA; NAOKI KUDA; NOBUHIKO TAKAJO; NOBUO TANAKA; NORIKO TOSHIMITSU; OSAMU ISHIHARA; SHIN TSUGAWA; SHINRO MATSUURA; SHOHEI KINOSHITA; SHOICHI IMAI; SHUICHI ARAMAKI; SHUNICHI DAI; TADAFUMI NISHIMURA; TAKASHI MOTOHIRO; TAKESHI YUASA; TAKUYA FUJISAWA; TAMOTSU FUJIMOTO; TATSUHIKO KOGA; TOHRU NISHIYAMA; TSUKASA IRIKI; YASUSHI SHIMADA; YASUTAKA SAKATA; YOSHIHARU KOMATSU; YOSHIMI TANAKA; YUJI YAMASHITA; YUKIHIKO KATABUCHI; YUSUKE SAKAGUCHI; YUTAKA HARADA; YUTAKA ISHIKAWA; 久保田 薫; 久田 直樹; 今井 昌一; 入来 典; 冨田 尚文; 利光 紀子; 加藤 栄司; 原 貴美子; 原田 素彦; 原田 豊; 古賀 達彦; 吉本 賢良; 坂口 祐助; 坂本 博文; 堀川 瑞穂; 大滝 悦生; 大部 敬三; 太田 正憲; 安藤 寛; 富永 薫; 小松 良治; 小野 栄一郎; 山下 文雄; 山下 祐二; 山本 正士; 島田 康; 川上 晃; 市川 光太郎; 平田 克彦; 広瀬 富士子; 弓削 建; 木下 昇平; 木村 建; 木村 昭彦; 本廣 孝; 松尾 宏; 松浦 伸郎; 梶山 純子; 森田 潤; 永山 清高; 江口 春彦; 津川 信; 浦部 大策; 湯浅 洗; 片渕 幸彦; 田中 信夫; 田中 地平; 田中 永一郎; 田中 祥視; 田中 耕一; 石原 修; 石川 豊; 石本 耕治; 織田 慶子; 臺 俊一; 荒木 久昭; 荒牧 修一; 藤本 保; 藤松 雅彦; 藤沢 卓爾; 西山 亨; 西村 忠史; 長 博雪; 阪田 保隆; 高城 信彦
Source
The Japanese Journal of Antibiotics. 1985, 38(8):2068
Subject
Language
Japanese
ISSN
0368-2781
2186-5477
2186-5477
Abstract
Dibekacin (DKB), an antibiotic of aminoglycoside group, was administered at 4 different dosages of 0. 5, 1. 0, 1. 5 and 2. 0 mg/kg as intravenous drip infusion taking 30 minutes or 1 hour. For each dose level, 3 cases each were used out of 24 boys from 1 year and 1 month to 14 years and 7 months of age, and serum concentrations as well as urinary concentrations and recovery rate were determined. After removed of 4 cases unassessable of therapeutic efficacy, 7 cases consisting of 1 case of chronic bronchitis, 1 case of lung abscess and 5 cases of urinary tract infections were treated with DKB at a mean daily dosage of 3. 3 mg/kg in 2 or 3 divided doses as intravenous drip infusion taking 30 minutes or 1 hour. The mean treatment period was 7 days. The clinical and bacteriological results were analyzed in these cases and for analysis of side effects drop out cases were also included. The following results were obtained.1. Following 30 minutes intravenous drip infusion of DKB at 0. 5, 1. 0, 1. 5 and 2. 0 mg/kg, the serum concentration peaked at the end of infusion for all dose levels. The highest peak concentration of 9. 17mcg/ml was obtained for the dose level of 2. 0mg/kg. The highest dosage with which serum concentration does not exceed concentrations of 10 to 12mcg/ml was found to be 2. 0mg/kg. The mean highest serum concentrations obtained were 1. 65, 3. 49, 5. 40 and 8. 67mcg/ml for the dosages of 0. 5, 1. 0, 1.5 and 2.0 mg/kg, respectively, and the mean AUCs determined by the two-compartment model were 2. 99, 6. 04, 10 5 and 14.2mcg·hr/ml, respectively, showing dose response relation in terms of peak concentration and AUC among groups. The mean T1/2 values for each dosage were 1. 55, 1. 54, 1. 77 and 2. 03 hours, respectively, with a longer tendency in T1/2 for the dose level of 2. 0mg/kg with unknown cause.When 0. 5, 1. 0, 1. 5 and 2. 0 mg/kg of DKB were infused taking 1 hour, the peak of serum concentration appeared also at the end of the infusion. The highest concentration was obtained with 2. 0mg/kg and it was 7. 02mcg/ml. Considering from the concentrations obtained for 0. 5mg/kg and 1. 0mg/kg groups the highest dosage at which the serum concentration does not exceed 10 to 12mcg/ml was estimated to be 2. 5mg/kg. The mean highest serum concentrations for dose levels of 0. 5, 1. 0, 1. 5 and 2. 0mg/kg were 1. 61, 3. 75, 4. 80 and 5. 68mcg/ml, respectively. Except for 1. 0 mg/kg group the serum concentrations obtained with 1 hour intravenous drip infusions were slightly lower than those with 30 minutes intravenous drip infusions. A dose response relation was observed among each group. While were some cases in which AUC could not be determined by the two-compartment model, the analysis of results by the one-compartment model revealed dose response relation among groups. As to T1/2 no comparison could be made by mean values. However, from the results of the analysis by the one-compartment model no remarkable difference was shown in T1/2 between 30 minutes drip infusions and 1 hour drip infusions.2. Following both 30 minutes and 1 hour intravenous drip infusions the urinary concentration reached its highest value at 1 to 2 hours period most frequently, followed by 2 to 3 hours period. The urinary recovery rate within the first 7 hours following 30 minutes infusion was 42. 3, 49. 7, 59. 3 and 55. 1% for 0. 5, 1. 0, 1. 5 and 2. 0mg/kg, respectively, with corresponding figures being 58. 9, 65. 2, 55. 6 and 46. 9%, respectively, for 1 hour drip infusion.3. Clinical efficacy was rated as good or excellent in 5 cases of urinary tract infections out of 7 cases.4. Out of these 7 cases, disappearance of organisms could be obtained in all of 5 cases which could be assessed of bacteriological efficacy. In 1 of these cases of urinary tract infections, the change pattern of organisms from P. aeruginosa to E. faecalis was observed.